Stock and performance unit awards to Indivior (INDV) CFO Ryan Preblick

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc.’s Chief Financial Officer Ryan Preblick reported equity awards rather than open-market trades. He received a grant of 37,358 restricted stock units with a stated price of $0, increasing his directly held common stock to 317,940 shares after the award.

He was also credited with 113,510 performance stock units at an exercise price of $0. These relate to a conditional award originally granted on March 3, 2023, for 113,510 shares, with performance conditions certified on February 9, 2026. The award is scheduled to vest on March 3, 2026 and then remain subject to a further two-year holding period before the vested shares are released. The RSUs vest in three equal annual installments beginning February 10, 2027, conditioned on his continued service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Preblick Ryan

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		37,358(1)	A	$0	317,940	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	$0	02/09/2026		A		113,510		03/03/2028(2)	(2)	Common Stock	113,510	$0	113,510	D

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.

2. On March 3, 2023, the Reporting Person was granted a conditional award for 113,510 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026. The shares will then be subject to an additional two-year Holding Period before the vested Shares are released to the Reporting Person.

Remarks:

Exhibit 24 Power of Attorney

	/s/Alice Givens, Power of Attorney	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Indivior (INDV) report for CFO Ryan Preblick?

Indivior reported that CFO Ryan Preblick received equity awards, not open-market trades. He acquired 37,358 restricted stock units and 113,510 performance stock units at a stated price of $0 per unit as part of his compensation, increasing his direct equity exposure.

How many Indivior (INDV) common shares does the CFO hold after this Form 4?

After the reported restricted stock unit grant, CFO Ryan Preblick beneficially owns 317,940 shares of Indivior common stock directly. This figure reflects his holdings following the February 10, 2026 award of 37,358 restricted stock units reported in the Form 4 filing.

What are the vesting terms of the 37,358 RSUs granted to Indivior (INDV)’s CFO?

The 37,358 restricted stock units vest in three equal annual installments beginning on February 10, 2027. Each RSU represents a contingent right to receive one Indivior common share, subject to Ryan Preblick’s continued service with the company through each applicable vesting date.

What performance stock unit award did Indivior (INDV) disclose for its CFO?

Indivior disclosed 113,510 performance stock units for CFO Ryan Preblick at a $0 exercise price. These relate to a conditional award granted March 3, 2023, with performance conditions certified on February 9, 2026, and scheduled to vest on March 3, 2026, subject to continued employment.

Is there an additional holding period on the Indivior (INDV) performance stock units?

Yes. After vesting on March 3, 2026, the 113,510 performance-linked shares are subject to an additional two-year holding period. During this time, the vested shares are not released to CFO Ryan Preblick until completion of the holding period described in the award terms.

Are the reported Indivior (INDV) equity awards purchases on the open market?

No. The Form 4 describes awards coded as acquisitions under compensation arrangements, not open-market purchases. Both the 37,358 restricted stock units and 113,510 performance stock units were granted at a stated price of $0, reflecting incentive compensation rather than cash share purchases.